<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03984149</url>
  </required_header>
  <id_info>
    <org_study_id>LIPIGEN-002</org_study_id>
    <nct_id>NCT03984149</nct_id>
  </id_info>
  <brief_title>Lipa Gene Mutation in PED-LIPIGEN (Pediatric FH Subjects)</brief_title>
  <official_title>Prevalence and Mutation Rate of Lipa Gene in LIPIGEN Subjects With Clinical Diagnosis of FH</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fondazione SISA (Societa Italiana per lo Studio della Arteriosclerosi)</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Fondazione SISA (Societa Italiana per lo Studio della Arteriosclerosi)</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Familial Hypercholesterolemia (FH) is a monogenic autosomal dominant disease also known as
      Autosomal Dominant Hypercholesterolemia - ADH) that leads to dramatically increased levels of
      Low Density Lipoprotein (LDL) and total cholesterol associated to tendon xanthomas,
      xanthelasma, corneal arcus, premature atherosclerosis and to an increased risk of coronary
      artery disease (CAD) and myocardial infarction.

      FH is mainly caused by mutations in genes encoding for proteins affecting hepatic LDL
      cholesterol uptake including the LDL receptor (LDLR) gene or the gene encoding the only
      apolipoprotein of LDL, the apolipoprotein B (APOB), or the gene encoding a protease
      regulating LDLR levels on the cell membrane Lysosomal Acid Lipase A (LIPA) gene encode for
      Lysosomal acid lipase (LAL) enzyme responsible for hydrolyzing cholesterol esters and
      triglycerides that are delivered to lysosomes. Mutations in LIPA that completely inactivate
      LAL are the molecular cause of Wolman disease, a rapidly lethal disease of infancy while
      mutations in LIPA that result in residual enzymatic activity of LAL are responsible of a
      disorder characterized by a less severe phenotype known as cholesterol ester storage disease
      (CESD). Patients with CESD usually show a phenotype characterized by hepatic disease and
      mixed hyperlipidemia with elevated levels of LDL-C and triglycerides (TG) and decreased HDL-C
      levels.

      A broader phenotypic presentation for loss of function mutations in LIPA suggests that LIPA
      mutations may be considered in patients with apparently monogenic FH in whom mutations in the
      known candidate genes are not detectable.

      The project is aimed to evaluate the prevalence and the mutation rate of LIPA gene in
      subjects with a clinical diagnosis of FH and already genetically characterized in whom
      pathogenic mutations in the known candidate genes have not been identified. The analysis will
      be performed in about 250 FH pediatric subjects and putative causal mutations will be also
      tested for co-segregation in available families in affected and unaffected members.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Lysosomal acid lipase (LAL) is encoded by LIPA gene located on chromosome 10q23.3-q23 and
      consists of 10 exons. LIPA mRNA (messenger RiboNucleic Acid) (GenBank accession number
      NM_000235) is 2782 bp long and encodes a mature protein of 375 residues (GenBank accession
      number NP_000226). The sequencing of all 10 exons of LIPA gene will consist of 10 PCR
      (Polymerase Chain Reaction) amplification reactions (for the 10 exons and the proximal
      promoter) followed by 20 sequence reactions (forward and reverse sequencing) with appropriate
      primers designed to include the intron-exon boundaries. This analysis will be performed in
      about 250 FH pediatric subjects as specified in project description.

      The sequencing work will be performed taking advantage of 2 automated 8 capillaries automated
      DNA Sequencer (3500 Genetic Analyzer, Thermo Fisher Scientific, Monza, Italy) currently
      available in the laboratory of the Units involved in the project.

      In case of identification of unreported sequence variants, the presence of these mutations
      will be assessed in a sample of at least 100 normolipidemic subjects of the population, in
      order to define whether the nucleotide changes are rare sequence variations (with a putative
      functional effect) or represent common polymorphisms. In case of finding of rare variants in
      the coding regions, an in silico analysis will be performed by using two different softwares
      (Polyphen, http://genetics.bwh.harvard.edu/pph/ and Panther, http://www.pantherdb.org/) to
      predict the putative damaging role of the mutations on the protein. In case of intronic
      variants, the specifically designed software Automated Splice Site Analysis will be applied
      (https://www.splice.uwo.ca/).

      Putative causal mutations will be also tested for co-segregation in available families in
      affected and unaffected members.

      In order to test the effect of variants on enzyme activity LAL-activity will be assayed with
      dried blood spot (DBS) technique using the inhibitors Lalistat 2 in carriers and non carriers
      of these mutations belonging to available kindred.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 1, 2017</start_date>
  <completion_date type="Anticipated">July 1, 2021</completion_date>
  <primary_completion_date type="Anticipated">July 1, 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Other</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Prevalence of patients with mutations of LIPA gene among clinically diagnosed FH subjects</measure>
    <time_frame>2 years from start of the study</time_frame>
    <description>Percentage of patients with at least one mutation of LIPA gene among clinically diagnosed FH subjects according to a &quot;Dutch Lipid Clinic Network&quot; score of 6 or above</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Frequency of specific mutations of LIPA gene among clinically diagnosed FH subjects</measure>
    <time_frame>2 years from start of the study</time_frame>
    <description>Numbers of patients carrying specific mutations of LIPA gene among clinically diagnosed FH subjects for each mutation identified by sequencing of all 10 exons of LIPA gene.</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">1000</enrollment>
  <condition>Lysosomal Acid Lipase Deficiency</condition>
  <arm_group>
    <arm_group_label>FH pediatric patients</arm_group_label>
    <description>1000 clinically diagnosed FH pediatric patients (age &lt;18 years) included in the LIPIGEN (Lipid TransPort Disorders italian Genetic Network) database</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Observational study</intervention_name>
    <description>Observational study: There is no intervention.</description>
    <arm_group_label>FH pediatric patients</arm_group_label>
  </intervention>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Venous blood samples were taken after 12 hours of fasting. Serum total cholesterol,
      triglycerides and HDL-cholesterol levels were measured in a centralized laboratory using
      enzymatic methods.

      DNA samples, serum, plasma and whole blood were aliquoted and preserved at -80°C.
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Clinically diagnosed FH pediatric patients (age &lt;18 years) included in the Lipid TransPort
        Disorders italian Genetic Network (LIPIGEN) database, already genetically characterized.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Pediatric subjects (&lt;18 years old) with a clinical diagnosis of FH and without
             identified pathogenic mutations in the known candidate genes.

        Exclusion Criteria:

          -  Subjects with a clinical diagnosis of FH with identified pathogenic mutations in the
             known candidate genes.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>18 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Maurizio Averna</last_name>
    <role>Study Director</role>
    <affiliation>Fondazione SISA</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Alberico L Catapano</last_name>
    <email>alberico.catapano@unimi.it</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Alessia Tincani</last_name>
    <phone>+39026173276</phone>
    <email>catapano.centroatero@gmail.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>CENTRO PER LO STUDIO DELL'ATEROSCLEROSI - Ospedale Bassini</name>
      <address>
        <city>Cinisello Balsamo</city>
        <state>Mi</state>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alberico L Catapano</last_name>
      <email>alberico.catapano@unimi.it</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Laboratorio di biochimica delle lipoproteine - DIPARTIMENTO DI SCIENZE BIOMEDICHE</name>
      <address>
        <city>Modena</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Patrizia M. Tarugi</last_name>
      <email>patriziamaria.tarugi@unimore.it</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Centro Di Riferimento Regionale Per La Prevenzione, Diagnosi E Cura Delle Malattie Rare Del Metabolismo</name>
      <address>
        <city>Palermo</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Maurizio Averna</last_name>
      <email>maurizio.averna@unipa.it</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Centro Per L'Arteriosclerosi Dipartimento Di Medicina Interna E Specialità Mediche</name>
      <address>
        <city>Roma</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marcello Arca</last_name>
      <email>marcello.arca@uniroma1.it</email>
    </contact>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <link>
    <url>https://apps.who.int/iris/handle/10665/66346</url>
    <description>Familial hypercholesterolaemia (FH) : report of a second World Health Organization (WHO) consultation, Geneva, 4 September 1998</description>
  </link>
  <reference>
    <citation>ABRAMOV A, SCHORR S, WOLMAN M. Generalized xanthomatosis with calcified adrenals. AMA J Dis Child. 1956 Mar;91(3):282-6.</citation>
    <PMID>13301142</PMID>
  </reference>
  <reference>
    <citation>Bernstein DL, Hülkova H, Bialer MG, Desnick RJ. Cholesteryl ester storage disease: review of the findings in 135 reported patients with an underdiagnosed disease. J Hepatol. 2013 Jun;58(6):1230-43. doi: 10.1016/j.jhep.2013.02.014. Epub 2013 Feb 26. Review.</citation>
    <PMID>23485521</PMID>
  </reference>
  <reference>
    <citation>Bertolini S, Pisciotta L, Rabacchi C, Cefalù AB, Noto D, Fasano T, Signori A, Fresa R, Averna M, Calandra S. Spectrum of mutations and phenotypic expression in patients with autosomal dominant hypercholesterolemia identified in Italy. Atherosclerosis. 2013 Apr;227(2):342-8. doi: 10.1016/j.atherosclerosis.2013.01.007. Epub 2013 Jan 19.</citation>
    <PMID>23375686</PMID>
  </reference>
  <reference>
    <citation>Burke JA, Schubert WK. Deficient activity of hepatic acid lipase in cholesterol ester storage disease. Science. 1972 Apr 21;176(4032):309-10.</citation>
    <PMID>5019788</PMID>
  </reference>
  <reference>
    <citation>Futema M, Plagnol V, Li K, Whittall RA, Neil HA, Seed M; Simon Broome Consortium, Bertolini S, Calandra S, Descamps OS, Graham CA, Hegele RA, Karpe F, Durst R, Leitersdorf E, Lench N, Nair DR, Soran H, Van Bockxmeer FM; UK10K Consortium, Humphries SE. Whole exome sequencing of familial hypercholesterolaemia patients negative for LDLR/APOB/PCSK9 mutations. J Med Genet. 2014 Aug;51(8):537-44. doi: 10.1136/jmedgenet-2014-102405. Epub 2014 Jul 1.</citation>
    <PMID>24987033</PMID>
  </reference>
  <reference>
    <citation>Hamilton J, Jones I, Srivastava R, Galloway P. A new method for the measurement of lysosomal acid lipase in dried blood spots using the inhibitor Lalistat 2. Clin Chim Acta. 2012 Aug 16;413(15-16):1207-10. doi: 10.1016/j.cca.2012.03.019. Epub 2012 Mar 29.</citation>
    <PMID>22483793</PMID>
  </reference>
  <reference>
    <citation>Hopkins PN, Toth PP, Ballantyne CM, Rader DJ; National Lipid Association Expert Panel on Familial Hypercholesterolemia. Familial hypercholesterolemias: prevalence, genetics, diagnosis and screening recommendations from the National Lipid Association Expert Panel on Familial Hypercholesterolemia. J Clin Lipidol. 2011 Jun;5(3 Suppl):S9-17. doi: 10.1016/j.jacl.2011.03.452. Epub 2011 Apr 3.</citation>
    <PMID>21600530</PMID>
  </reference>
  <reference>
    <citation>Nordestgaard BG, Chapman MJ, Humphries SE, Ginsberg HN, Masana L, Descamps OS, Wiklund O, Hegele RA, Raal FJ, Defesche JC, Wiegman A, Santos RD, Watts GF, Parhofer KG, Hovingh GK, Kovanen PT, Boileau C, Averna M, Borén J, Bruckert E, Catapano AL, Kuivenhoven JA, Pajukanta P, Ray K, Stalenhoef AF, Stroes E, Taskinen MR, Tybjærg-Hansen A; European Atherosclerosis Society Consensus Panel. Familial hypercholesterolaemia is underdiagnosed and undertreated in the general population: guidance for clinicians to prevent coronary heart disease: consensus statement of the European Atherosclerosis Society. Eur Heart J. 2013 Dec;34(45):3478-90a. doi: 10.1093/eurheartj/eht273. Epub 2013 Aug 15.</citation>
    <PMID>23956253</PMID>
  </reference>
  <reference>
    <citation>Patrick AD, Lake BD. Deficiency of an acid lipase in Wolman's disease. Nature. 1969 Jun 14;222(5198):1067-8.</citation>
    <PMID>5787090</PMID>
  </reference>
  <reference>
    <citation>Risk of fatal coronary heart disease in familial hypercholesterolaemia. Scientific Steering Committee on behalf of the Simon Broome Register Group. BMJ. 1991 Oct 12;303(6807):893-6.</citation>
    <PMID>1933004</PMID>
  </reference>
  <reference>
    <citation>Stitziel NO, Fouchier SW, Sjouke B, Peloso GM, Moscoso AM, Auer PL, Goel A, Gigante B, Barnes TA, Melander O, Orho-Melander M, Duga S, Sivapalaratnam S, Nikpay M, Martinelli N, Girelli D, Jackson RD, Kooperberg C, Lange LA, Ardissino D, McPherson R, Farrall M, Watkins H, Reilly MP, Rader DJ, de Faire U, Schunkert H, Erdmann J, Samani NJ, Charnas L, Altshuler D, Gabriel S, Kastelein JJ, Defesche JC, Nederveen AJ, Kathiresan S, Hovingh GK; National Heart, Lung, and Blood Institute GO Exome Sequencing Project. Exome sequencing and directed clinical phenotyping diagnose cholesterol ester storage disease presenting as autosomal recessive hypercholesterolemia. Arterioscler Thromb Vasc Biol. 2013 Dec;33(12):2909-14. doi: 10.1161/ATVBAHA.113.302426. Epub 2013 Sep 26.</citation>
    <PMID>24072694</PMID>
  </reference>
  <reference>
    <citation>Talmud PJ, Futema M, Humphries SE. The genetic architecture of the familial hyperlipidaemia syndromes: rare mutations and common variants in multiple genes. Curr Opin Lipidol. 2014 Aug;25(4):274-81. doi: 10.1097/MOL.0000000000000090.</citation>
    <PMID>24977977</PMID>
  </reference>
  <reference>
    <citation>Williams RR, Hunt SC, Schumacher MC, Hegele RA, Leppert MF, Ludwig EH, Hopkins PN. Diagnosing heterozygous familial hypercholesterolemia using new practical criteria validated by molecular genetics. Am J Cardiol. 1993 Jul 15;72(2):171-6.</citation>
    <PMID>8328379</PMID>
  </reference>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>May 21, 2019</study_first_submitted>
  <study_first_submitted_qc>June 11, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">June 12, 2019</study_first_posted>
  <last_update_submitted>July 22, 2020</last_update_submitted>
  <last_update_submitted_qc>July 22, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 23, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Atherosclerosis</keyword>
  <keyword>Familial hypercholesterolemia</keyword>
  <keyword>LIPA</keyword>
  <keyword>Lysosomal acid lipase deficiency</keyword>
  <keyword>Wolman disease</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Wolman Disease</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Upon preventive request for a scientific collaboration</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_info_type>Informed Consent Form (ICF)</ipd_info_type>
    <ipd_info_type>Clinical Study Report (CSR)</ipd_info_type>
    <ipd_info_type>Analytic Code</ipd_info_type>
    <ipd_time_frame>For three years from the end of the study</ipd_time_frame>
    <ipd_access_criteria>Upon preventive request for a scientific collaboration</ipd_access_criteria>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

